Clinical Policy: Lerodalcibep-liga (Lerochol)
Customize your policy alerts
Sign up for QualChoice Policy CP.PHAR.768 alerts
Get alerted when Policy CP.PHAR.768 changes without checking for updates manually.
Monitor payer policy activity
This policy defines medical necessity and prior authorization criteria for lerodalcibep-liga (Lerochol) for adults with hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) across QualChoice lines of business.
No material clinical or coverage changes in this revision.
Coverage Criteria for Lerodalcibep-liga (Lerochol)
Initial Therapy
Covered when ALL of the following are met for Initial Approval — Primary Hypercholesterolemia (including HeFH) and CV event risk reduction:
See Appendix D for diagnostic scoring and Appendix F/G for contraindication and intolerance definitions.
Continuation Therapy
Covered when ALL of the following are met for Continued Therapy — Primary Hypercholesterolemia (including HeFH) and CV event risk reduction:
Approval durations: Medicaid/HIM 12 months; Commercial 6 months or to renewal date.
Non‑FDA approved indications not specifically addressed in this policy are not authorized for coverage unless the provider supplies sufficient clinical documentation demonstrating efficacy and safety in accordance with the applicable off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid).
Contraindications relevant to background statin therapy include: decompensated liver disease (eg, jaundice, ascites, variceal bleeding, encephalopathy); laboratory‑confirmed acute liver injury or statin‑related rhabdomyolysis; pregnancy, actively trying to become pregnant, or nursing; and immune‑mediated hypersensitivity to the statin class (documented allergic reaction to at least two different statins). For ezetimibe, contraindications include moderate or severe hepatic impairment (Child‑Pugh B or C) and documented hypersensitivity to ezetimibe.
When state Medicaid coverage provisions conflict with this clinical policy, the state Medicaid provisions take precedence. Providers should consult the applicable state Medicaid manual for any state‑specific coverage rules that supersede this policy.
Coding and LDL Thresholds
Provider Actions, Documentation, and Authorization Requirements
Prior authorization: preferred PCSK9 trial required
Prior authorization requests must include evidence that the member failed an 8-week trial of a preferred PCSK9 inhibitor at maximally indicated doses when applicable; Illinois HIM requests are exempt from this step therapy requirement per IL HB 5395 (effective 1/1/2026).
- Failure defined as intolerance or inadequate response after an 8-week trial at up to maximally indicated doses.
- State law exception: IL HB 5395 removes the step therapy requirement for Illinois HIM requests.
Confirm labeled dose and product strength on PA
Prior authorization and approval should reflect the labeled dosing regimen of 300 mg subcutaneously once monthly and the product presentation of a single-use pre-filled syringe 300 mg/1.2 mL.
- Labeled dosing: 300 mg SC monthly.
- Product supplied as single-use pre-filled syringe 300 mg/1.2 mL.
Obtain prior authorization and code appropriately (J3590, C9399)
When requesting prior authorization and when submitting claims, reference the HCPCS listings in the policy; the document notes J3590 and C9399 as the codes referenced, and providers should obtain prior authorization per payer processes when billing these codes.
Step therapy and background lipid‑lowering therapy required
Approval requires failure of a preferred PCSK9 inhibitor trial and documentation of adherence to maximally tolerated statin (or documented statin contraindication/intolerance); ezetimibe adherence when used concomitantly is also required per initial criteria.
- 8-week trial of a preferred PCSK9 inhibitor at maximally indicated doses unless contraindicated or intolerant.
- If on statin: Lerochol must be prescribed with a statin at maximally tolerated dose and member adherent for at least the last 8 weeks.
- Member must have been adherent to ezetimibe used with a statin for at least the last 4 months unless contraindicated or intolerant.
Document concomitant maximally tolerated statin therapy
Document concomitant maximally tolerated statin therapy when applicable; patients should remain on statin therapy if tolerated and statin intensity classifications (high/moderate) are provided in the appendices.
- If statin tolerant, Lerochol must be prescribed with a statin at the maximally tolerated dose (see Appendix E for high-intensity and Appendix for moderate-intensity examples).
- Patients should remain on concomitant statin therapy if tolerated due to long-term cardiovascular benefits.
No other explicit step therapy steps listed here
The policy notes no additional explicit step therapy requirements in the surrounding document window beyond the stated preferred PCSK9 trial and statin/ezetimibe background therapy; check state exceptions (e.g., IL HB 5395) for applicability.
- No other explicit step therapy steps are listed in this section beyond the preferred PCSK9 trial and statin/ezetimibe requirements.
- Verify state-specific exceptions such as Illinois HIM under IL HB 5395.
Submit clinical documentation and recent LDL‑C
Providers must submit office chart notes, laboratory results, or other clinical information supporting that the member has met all approval criteria, including a recent LDL‑C measured within the last 60 days and documentation of prior therapy trials and statin/ezetimibe adherence.
- Include recent LDL‑C within 60 days demonstrating threshold criteria.
- Include documentation of prior PCSK9 trial, statin adherence/intolerance, and ezetimibe use where applicable.
Provide HeFH diagnostic documentation per formal criteria
For HeFH diagnoses, include documentation per the Dutch Lipid Clinic Network or Simon Broome criteria — e.g., scoring across family history, clinical history, physical exam, cholesterol levels (LDL‑C bands) and DNA analysis when available — and record family history details as applicable.
- Use Dutch Lipid Clinic Network scoring (choose highest score in each category and sum) with LDL‑C bands (e.g., ≥330; 250–329; 190–249; 155–189 mg/dL).
- Simon Broome criteria: elevated total cholesterol or LDL plus tendinous xanthomas or DNA evidence of LDL receptor mutation.
Consult prescribing information and cited guidelines
Consult the policy references and the Lerochol Prescribing Information and referenced guideline documents for clinical details and prescribing requirements; these materials are cited in the policy.
- Key reference: Lerochol Prescribing Information (LIB Therapeutics, Dec 2025).
- Additional guideline references provided (ACC/AHA, NLA, etc.) for clinical guidance.
Insufficient documentation or off‑label requests risk denial
Failure to provide required documentation that the member meets all approval criteria, or requests for non‑FDA indicated uses without supporting evidence per off‑label use policies, may result in denial of the request.
- Non‑FDA indications are not authorized unless sufficient documentation per off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) is provided.
- Lack of supporting clinical documentation for criteria may lead to denial.
Dose exceedance (>300 mg/month) will not conform to policy
Requests for doses above the policy maximum would not conform to the stated dosing regimen; the maximum allowed dose is 300 mg per month.
- Maximum dose per policy: 300 mg/month. Requests exceeding this (greater than 300 mg/month) are nonconforming.
Coding inclusion/exclusion does not guarantee coverage — verify guidance
The policy includes HCPCS codes for informational purposes only and warns that inclusion or exclusion of any codes does not guarantee coverage; providers should verify current coding guidance before submitting claims.
Background on Lerodalcibep-liga (Lerochol)
Lerodalcibep‑liga (Lerochol) is a PCSK9‑targeted therapy indicated as an adjunct to diet and exercise to reduce LDL‑C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The policy aligns use of Lerochol with background statin and ezetimibe therapy and specifies the labeled dosing of 300 mg subcutaneously once monthly and the supplied presentation as a single‑use pre‑filled syringe (300 mg/1.2 mL).
Definitions and Product Presentation
Initial Therapy Criteria and Dosing
Initial Therapy — Initial approval requires meeting diagnostic, specialist prescriber, age, prior therapy, statin/ezetimibe, LDL-C, drug interaction, and dosing conditions.
Initial approval requires meeting diagnostic, specialist prescriber, age, prior therapy, statin/ezetimibe, LDL‑C, drug interaction, and dosing conditions.
Providers must submit supporting chart notes and labs (recent LDL‑C within 60 days), and documentation for prior therapies, HeFH diagnostic criteria, and statin/ezetimibe adherence.
Initial Therapy — Labeled initial dosing.
Labeled initial dosing.
Product presentation: single‑use prefilled syringe 300 mg/1.2 mL (see product information).
Initial/Standard Dosing
Dosing for initial and routine therapy.
Maximum monthly dose = 300 mg.
Continuation Criteria
Continued Therapy
Continuation criteria require evidence of benefit and adherence.
Approval duration varies by line of business (Medicaid/HIM 12 months; Commercial 6 months or to renewal).
Concomitant therapy — Guidance for ongoing therapy and maintaining statin if tolerated.
Guidance for ongoing therapy and maintaining background lipid‑lowering treatment.
Appendices provide statin intensity definitions, contraindications, and SAMS diagnostic/rechallenge guidance.
Step Therapy Requirements
| Step | Requirement | Notes / Exceptions |
|---|---|---|
| 1 | Trial of a preferred PCSK9 inhibitor for 8 weeks at maximally indicated doses prior to Lerochol | For Illinois HIM requests, the step therapy requirement does not apply per IL HB 5395 (effective 1/1/2026). Prior authorization may be required for PCSK9 inhibitors. |
| Step | Requirement | Notes |
|---|---|---|
| 1 | Lerochol must be prescribed in conjunction with a statin at the maximally tolerated dose when the member is statin tolerant; document adherence for at least the last 8 weeks | Patients should remain on concomitant statin therapy if tolerated due to established long‑term cardiovascular benefits. See Appendices for high- and moderate-intensity statin dose examples. |
Quantity Limits and Dosing Caps
Site of Care and Administration
Product presentation: single‑use 300 mg/1.2 mL pre-filled syringe
The product is supplied as a single‑use pre-filled syringe (300 mg/1.2 mL) intended for subcutaneous administration; documentation of the supplied presentation may be included with prior authorization.
Site of care: pre-filled syringe; setting not restricted
Product supply is a single‑use pre-filled syringe suitable for subcutaneous administration; the policy does not restrict site of care in this section.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.